Donte Group, Spiral, Telefónica, Google Cloud and Universidad CEU San Pablo have agreed to collaborate on a biomedical analysis of oral dysbiosis to include it as a risk factor in the development of systemic diseases.
According to its promoters, the bioinformatics analysis will be carried out by means of artificial intelligence and Big Data storage. The innovative large-scale scientific study, with more than 2,200 volunteers, will be conducted in Spain through the Donte Group dental clinics and will last approximately three years.
According to Dr. Ana Adell Perez, principal investigator of the dental research team at the Universidad CEU San Pablo of Madrid, “the importance and association of the oral microbiota with the general health of the patient is increasingly close. A significant number of recent scientific studies and publications attest to this”.
Many of these studies suggest that having certain bacterial species in a high degree of uncontrolled infection predisposes the patient to suffer from certain types of chronic non-communicable diseases, such as cardiovascular disease, stroke, colon cancer, diabetes, adverse effects on pregnancy, etc. However, the exact mechanisms of interaction between the oral microbiota and the rest of our organism are still unknown.
“This groundbreaking scientific study will highlight the important correlation of dental, medical and scientific information. The study will allow the development of new therapies and new personalized treatments for the patient’s health, covering all angles” said Spiral’s CEO, Francisco Tercero-Mora.
BACTERIOLOGICAL GENETIC TESTS
The procedure will consist of anonymous and voluntary collection of the necessary information from Donte Group patients through Spiral’s bacteriological genetic tests. Through this protocol and the use of new technologies from Telefónica and Google, it will be possible to associate all the clinical information and determine the existing relationship between the bacterial species of the oral microbiota, together with other parameters, and determine the relationship of oral dysbiosis as a risk factor for developing chronic non-communicable diseases.
“The results of the study, will impact the way we see and understand oral health as an essential part of the patient’s overall health, and will change the way we treat the oral cavity as an isolated organ of our body,” highlighted Donte Group’s medical director, Dr. Clara Esteban.
Francisco Tercero-Mora CEO of Spiral indicated that “We will be able to establish and incorporate new risk factors that will help us to prevent, diagnose and treat pathologies that in principle were not thought to have such an intimate relationship with the patient’s oral cavity”.